Werner Gladdines

Werner Gladdines joined Immunic in January 2021 as Head of the IMU-838 Program. Since then, he has held positions of increasing responsibility and was appointed Vice President, Program Management & Clinical Development Operations in February 2023 and Chief Development Officer in July 2024.

Mr. Gladdines has more than 20 years of experience in building and leading global drug development, clinical operations and clinical sciences teams in oncology, neurology and rare disease therapeutic areas across different commercial and clinical-stage biotechnology companies, including AIMM Therapeutics B.V., Rainier Therapeutics, Inc., Biomarin Pharmaceutical Inc., Prosensa Therapeutics B.V., to-BBB technologies B.V. and Genzyme Corp..

During his career, Mr. Gladdines has also executed strategic development and operational plans that have delivered timely and meaningful therapies for patients and has actively contributed to the registration of three medicinal products and the succesful delivery of over 20 international phase 1 to phase 4 clinical studies.

Mr. Gladdines earned a master’s degree in bio-pharmaceutical sciences from the University of Leiden, The Netherlands, where he focused on developing mathematical models describing concentration-effect relationships of neuroactive steroids. Mr. Gladdines is a frequent guest speaker at clinical research industry conferences.